HRP20161205T1 - Novi nitrozo spojevi kao donori nitroksila i metode za njihovu upotrebu - Google Patents
Novi nitrozo spojevi kao donori nitroksila i metode za njihovu upotrebu Download PDFInfo
- Publication number
- HRP20161205T1 HRP20161205T1 HRP20161205TT HRP20161205T HRP20161205T1 HR P20161205 T1 HRP20161205 T1 HR P20161205T1 HR P20161205T T HRP20161205T T HR P20161205TT HR P20161205 T HRP20161205 T HR P20161205T HR P20161205 T1 HRP20161205 T1 HR P20161205T1
- Authority
- HR
- Croatia
- Prior art keywords
- compound
- nitrosotetrahydro
- pyran
- substituted
- c8alkyl
- Prior art date
Links
- 150000002832 nitroso derivatives Chemical class 0.000 title claims 3
- ODUCDPQEXGNKDN-UHFFFAOYSA-N nitroxyl Chemical compound O=N ODUCDPQEXGNKDN-UHFFFAOYSA-N 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims 20
- 125000000623 heterocyclic group Chemical group 0.000 claims 10
- 206010019280 Heart failures Diseases 0.000 claims 8
- -1 amino, hydroxyl Chemical group 0.000 claims 7
- 206010007559 Cardiac failure congestive Diseases 0.000 claims 6
- 125000002252 acyl group Chemical group 0.000 claims 6
- 150000003839 salts Chemical class 0.000 claims 6
- 125000001424 substituent group Chemical group 0.000 claims 6
- 125000004423 acyloxy group Chemical group 0.000 claims 5
- 125000000217 alkyl group Chemical group 0.000 claims 5
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 5
- 125000001475 halogen functional group Chemical group 0.000 claims 5
- 125000004442 acylamino group Chemical group 0.000 claims 4
- 208000029078 coronary artery disease Diseases 0.000 claims 4
- 125000004093 cyano group Chemical group *C#N 0.000 claims 4
- 208000018578 heart valve disease Diseases 0.000 claims 4
- 125000001072 heteroaryl group Chemical group 0.000 claims 4
- 208000010125 myocardial infarction Diseases 0.000 claims 4
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 4
- 125000004043 oxo group Chemical group O=* 0.000 claims 4
- 150000003573 thiols Chemical class 0.000 claims 4
- 125000003118 aryl group Chemical group 0.000 claims 3
- 201000010099 disease Diseases 0.000 claims 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 3
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 claims 2
- 206010001935 American trypanosomiasis Diseases 0.000 claims 2
- 206010002383 Angina Pectoris Diseases 0.000 claims 2
- 206010003445 Ascites Diseases 0.000 claims 2
- 206010007556 Cardiac failure acute Diseases 0.000 claims 2
- 206010007572 Cardiac hypertrophy Diseases 0.000 claims 2
- 208000006029 Cardiomegaly Diseases 0.000 claims 2
- 208000024172 Cardiovascular disease Diseases 0.000 claims 2
- 208000024699 Chagas disease Diseases 0.000 claims 2
- 208000003037 Diastolic Heart Failure Diseases 0.000 claims 2
- 206010020772 Hypertension Diseases 0.000 claims 2
- 206010061216 Infarction Diseases 0.000 claims 2
- 206010048858 Ischaemic cardiomyopathy Diseases 0.000 claims 2
- 206010030124 Oedema peripheral Diseases 0.000 claims 2
- 208000025584 Pericardial disease Diseases 0.000 claims 2
- 206010037368 Pulmonary congestion Diseases 0.000 claims 2
- 206010037423 Pulmonary oedema Diseases 0.000 claims 2
- 206010063837 Reperfusion injury Diseases 0.000 claims 2
- 241000223109 Trypanosoma cruzi Species 0.000 claims 2
- 206010047295 Ventricular hypertrophy Diseases 0.000 claims 2
- PYFAZZJWSBOEAV-UHFFFAOYSA-N [4-(4-nitrosooxan-4-yl)oxy-4-oxobutyl] 2-acetyloxybenzoate Chemical compound CC(=O)OC1=CC=CC=C1C(=O)OCCCC(=O)OC1(N=O)CCOCC1 PYFAZZJWSBOEAV-UHFFFAOYSA-N 0.000 claims 2
- 230000001154 acute effect Effects 0.000 claims 2
- 125000003342 alkenyl group Chemical group 0.000 claims 2
- 125000003545 alkoxy group Chemical group 0.000 claims 2
- 125000004453 alkoxycarbonyl group Chemical group 0.000 claims 2
- 125000000304 alkynyl group Chemical group 0.000 claims 2
- 230000009787 cardiac fibrosis Effects 0.000 claims 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 2
- 230000007574 infarction Effects 0.000 claims 2
- 208000028867 ischemia Diseases 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 208000005333 pulmonary edema Diseases 0.000 claims 2
- 208000002815 pulmonary hypertension Diseases 0.000 claims 2
- 125000005017 substituted alkenyl group Chemical group 0.000 claims 2
- 125000000547 substituted alkyl group Chemical group 0.000 claims 2
- 125000004426 substituted alkynyl group Chemical group 0.000 claims 2
- 125000003107 substituted aryl group Chemical group 0.000 claims 2
- AOSZTAHDEDLTLQ-AZKQZHLXSA-N (1S,2S,4R,8S,9S,11S,12R,13S,19S)-6-[(3-chlorophenyl)methyl]-12,19-difluoro-11-hydroxy-8-(2-hydroxyacetyl)-9,13-dimethyl-6-azapentacyclo[10.8.0.02,9.04,8.013,18]icosa-14,17-dien-16-one Chemical compound C([C@@H]1C[C@H]2[C@H]3[C@]([C@]4(C=CC(=O)C=C4[C@@H](F)C3)C)(F)[C@@H](O)C[C@@]2([C@@]1(C1)C(=O)CO)C)N1CC1=CC=CC(Cl)=C1 AOSZTAHDEDLTLQ-AZKQZHLXSA-N 0.000 claims 1
- ABJSOROVZZKJGI-OCYUSGCXSA-N (1r,2r,4r)-2-(4-bromophenyl)-n-[(4-chlorophenyl)-(2-fluoropyridin-4-yl)methyl]-4-morpholin-4-ylcyclohexane-1-carboxamide Chemical compound C1=NC(F)=CC(C(NC(=O)[C@H]2[C@@H](C[C@@H](CC2)N2CCOCC2)C=2C=CC(Br)=CC=2)C=2C=CC(Cl)=CC=2)=C1 ABJSOROVZZKJGI-OCYUSGCXSA-N 0.000 claims 1
- GLGNXYJARSMNGJ-VKTIVEEGSA-N (1s,2s,3r,4r)-3-[[5-chloro-2-[(1-ethyl-6-methoxy-2-oxo-4,5-dihydro-3h-1-benzazepin-7-yl)amino]pyrimidin-4-yl]amino]bicyclo[2.2.1]hept-5-ene-2-carboxamide Chemical compound CCN1C(=O)CCCC2=C(OC)C(NC=3N=C(C(=CN=3)Cl)N[C@H]3[C@H]([C@@]4([H])C[C@@]3(C=C4)[H])C(N)=O)=CC=C21 GLGNXYJARSMNGJ-VKTIVEEGSA-N 0.000 claims 1
- QVHJQCGUWFKTSE-RXMQYKEDSA-N (2r)-2-[(2-methylpropan-2-yl)oxycarbonylamino]propanoic acid Chemical compound OC(=O)[C@@H](C)NC(=O)OC(C)(C)C QVHJQCGUWFKTSE-RXMQYKEDSA-N 0.000 claims 1
- IUSARDYWEPUTPN-OZBXUNDUSA-N (2r)-n-[(2s,3r)-4-[[(4s)-6-(2,2-dimethylpropyl)spiro[3,4-dihydropyrano[2,3-b]pyridine-2,1'-cyclobutane]-4-yl]amino]-3-hydroxy-1-[3-(1,3-thiazol-2-yl)phenyl]butan-2-yl]-2-methoxypropanamide Chemical compound C([C@H](NC(=O)[C@@H](C)OC)[C@H](O)CN[C@@H]1C2=CC(CC(C)(C)C)=CN=C2OC2(CCC2)C1)C(C=1)=CC=CC=1C1=NC=CS1 IUSARDYWEPUTPN-OZBXUNDUSA-N 0.000 claims 1
- YJLIKUSWRSEPSM-WGQQHEPDSA-N (2r,3r,4s,5r)-2-[6-amino-8-[(4-phenylphenyl)methylamino]purin-9-yl]-5-(hydroxymethyl)oxolane-3,4-diol Chemical compound C=1C=C(C=2C=CC=CC=2)C=CC=1CNC1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O YJLIKUSWRSEPSM-WGQQHEPDSA-N 0.000 claims 1
- VIJSPAIQWVPKQZ-BLECARSGSA-N (2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-acetamido-5-(diaminomethylideneamino)pentanoyl]amino]-4-methylpentanoyl]amino]-4,4-dimethylpentanoyl]amino]-4-methylpentanoyl]amino]propanoyl]amino]-5-(diaminomethylideneamino)pentanoic acid Chemical compound NC(=N)NCCC[C@@H](C(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(C)=O VIJSPAIQWVPKQZ-BLECARSGSA-N 0.000 claims 1
- WWTBZEKOSBFBEM-SPWPXUSOSA-N (2s)-2-[[2-benzyl-3-[hydroxy-[(1r)-2-phenyl-1-(phenylmethoxycarbonylamino)ethyl]phosphoryl]propanoyl]amino]-3-(1h-indol-3-yl)propanoic acid Chemical compound N([C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)O)C(=O)C(CP(O)(=O)[C@H](CC=1C=CC=CC=1)NC(=O)OCC=1C=CC=CC=1)CC1=CC=CC=C1 WWTBZEKOSBFBEM-SPWPXUSOSA-N 0.000 claims 1
- STBLNCCBQMHSRC-BATDWUPUSA-N (2s)-n-[(3s,4s)-5-acetyl-7-cyano-4-methyl-1-[(2-methylnaphthalen-1-yl)methyl]-2-oxo-3,4-dihydro-1,5-benzodiazepin-3-yl]-2-(methylamino)propanamide Chemical compound O=C1[C@@H](NC(=O)[C@H](C)NC)[C@H](C)N(C(C)=O)C2=CC(C#N)=CC=C2N1CC1=C(C)C=CC2=CC=CC=C12 STBLNCCBQMHSRC-BATDWUPUSA-N 0.000 claims 1
- UDQTXCHQKHIQMH-KYGLGHNPSA-N (3ar,5s,6s,7r,7ar)-5-(difluoromethyl)-2-(ethylamino)-5,6,7,7a-tetrahydro-3ah-pyrano[3,2-d][1,3]thiazole-6,7-diol Chemical compound S1C(NCC)=N[C@H]2[C@@H]1O[C@H](C(F)F)[C@@H](O)[C@@H]2O UDQTXCHQKHIQMH-KYGLGHNPSA-N 0.000 claims 1
- HUWSZNZAROKDRZ-RRLWZMAJSA-N (3r,4r)-3-azaniumyl-5-[[(2s,3r)-1-[(2s)-2,3-dicarboxypyrrolidin-1-yl]-3-methyl-1-oxopentan-2-yl]amino]-5-oxo-4-sulfanylpentane-1-sulfonate Chemical compound OS(=O)(=O)CC[C@@H](N)[C@@H](S)C(=O)N[C@@H]([C@H](C)CC)C(=O)N1CCC(C(O)=O)[C@H]1C(O)=O HUWSZNZAROKDRZ-RRLWZMAJSA-N 0.000 claims 1
- MPDDTAJMJCESGV-CTUHWIOQSA-M (3r,5r)-7-[2-(4-fluorophenyl)-5-[methyl-[(1r)-1-phenylethyl]carbamoyl]-4-propan-2-ylpyrazol-3-yl]-3,5-dihydroxyheptanoate Chemical compound C1([C@@H](C)N(C)C(=O)C2=NN(C(CC[C@@H](O)C[C@@H](O)CC([O-])=O)=C2C(C)C)C=2C=CC(F)=CC=2)=CC=CC=C1 MPDDTAJMJCESGV-CTUHWIOQSA-M 0.000 claims 1
- OMBVEVHRIQULKW-DNQXCXABSA-M (3r,5r)-7-[3-(4-fluorophenyl)-8-oxo-7-phenyl-1-propan-2-yl-5,6-dihydro-4h-pyrrolo[2,3-c]azepin-2-yl]-3,5-dihydroxyheptanoate Chemical compound O=C1C=2N(C(C)C)C(CC[C@@H](O)C[C@@H](O)CC([O-])=O)=C(C=3C=CC(F)=CC=3)C=2CCCN1C1=CC=CC=C1 OMBVEVHRIQULKW-DNQXCXABSA-M 0.000 claims 1
- KPSJTJFBBVWWDE-AWEZNQCLSA-N (4-nitrosooxan-4-yl) (2s)-2-acetamido-3-phenylpropanoate Chemical compound C([C@H](NC(=O)C)C(=O)OC1(CCOCC1)N=O)C1=CC=CC=C1 KPSJTJFBBVWWDE-AWEZNQCLSA-N 0.000 claims 1
- BSWTZLOUUZZHQQ-STQMWFEESA-N (4-nitrosooxan-4-yl) (2s,3s)-2,3,4-triacetyloxybutanoate Chemical compound CC(=O)OC[C@H](OC(C)=O)[C@H](OC(C)=O)C(=O)OC1(N=O)CCOCC1 BSWTZLOUUZZHQQ-STQMWFEESA-N 0.000 claims 1
- BFNQXNKNKJDFDE-UHFFFAOYSA-N (4-nitrosooxan-4-yl) 2,2,2-trichloroacetate Chemical compound ClC(Cl)(Cl)C(=O)OC1(N=O)CCOCC1 BFNQXNKNKJDFDE-UHFFFAOYSA-N 0.000 claims 1
- QELANUZLZOBYQL-UHFFFAOYSA-N (4-nitrosooxan-4-yl) 2,2,2-trifluoroacetate Chemical compound FC(F)(F)C(=O)OC1(N=O)CCOCC1 QELANUZLZOBYQL-UHFFFAOYSA-N 0.000 claims 1
- ZNUIEAFQUPMMSU-UHFFFAOYSA-N (4-nitrosooxan-4-yl) 2,2,3,3,3-pentafluoropropanoate Chemical compound FC(F)(F)C(F)(F)C(=O)OC1(N=O)CCOCC1 ZNUIEAFQUPMMSU-UHFFFAOYSA-N 0.000 claims 1
- DDQXTCPIRGKXSC-UHFFFAOYSA-N (4-nitrosooxan-4-yl) 2,2-dimethylpropanoate Chemical compound CC(C)(C)C(=O)OC1(N=O)CCOCC1 DDQXTCPIRGKXSC-UHFFFAOYSA-N 0.000 claims 1
- ORAHLTMGKJJONQ-UHFFFAOYSA-N (4-nitrosooxan-4-yl) 2-[acetyl(1,3-diacetyloxypropan-2-yl)amino]acetate Chemical compound CC(=O)OCC(COC(C)=O)N(C(C)=O)CC(=O)OC1(N=O)CCOCC1 ORAHLTMGKJJONQ-UHFFFAOYSA-N 0.000 claims 1
- WOTUDUNVHLIMQN-UHFFFAOYSA-N (4-nitrosooxan-4-yl) 2-acetamidopropanoate Chemical compound CC(=O)NC(C)C(=O)OC1(N=O)CCOCC1 WOTUDUNVHLIMQN-UHFFFAOYSA-N 0.000 claims 1
- ZGDNJHNGTVCISQ-UHFFFAOYSA-N (4-nitrosooxan-4-yl) 2-benzamidoacetate Chemical compound C=1C=CC=CC=1C(=O)NCC(=O)OC1(N=O)CCOCC1 ZGDNJHNGTVCISQ-UHFFFAOYSA-N 0.000 claims 1
- MRYDOZKNHJCPDN-UHFFFAOYSA-N (4-nitrosooxan-4-yl) 2-chloro-2,2-difluoroacetate Chemical compound FC(F)(Cl)C(=O)OC1(N=O)CCOCC1 MRYDOZKNHJCPDN-UHFFFAOYSA-N 0.000 claims 1
- LOQXJLVEDHHITC-UHFFFAOYSA-N (4-nitrosooxan-4-yl) 3,3,3-trifluoropropanoate Chemical compound FC(F)(F)CC(=O)OC1(N=O)CCOCC1 LOQXJLVEDHHITC-UHFFFAOYSA-N 0.000 claims 1
- TZDBHCYPUUCODV-UHFFFAOYSA-N (4-nitrosooxan-4-yl) 3-(5-oxooxolan-2-yl)propanoate Chemical compound C1CC(=O)OC1CCC(=O)OC1(N=O)CCOCC1 TZDBHCYPUUCODV-UHFFFAOYSA-N 0.000 claims 1
- WEZDOVOETDRARG-UHFFFAOYSA-N (4-nitrosooxan-4-yl) 3-acetyloxy-2-(acetyloxymethyl)-2-methylpropanoate Chemical compound CC(=O)OCC(C)(COC(C)=O)C(=O)OC1(N=O)CCOCC1 WEZDOVOETDRARG-UHFFFAOYSA-N 0.000 claims 1
- MIXUGPDBOLAYQB-UHFFFAOYSA-N (4-nitrosooxan-4-yl) 4,4,4-trifluorobutanoate Chemical compound FC(F)(F)CCC(=O)OC1(N=O)CCOCC1 MIXUGPDBOLAYQB-UHFFFAOYSA-N 0.000 claims 1
- BWNIHXYJOYWRJE-UHFFFAOYSA-N (4-nitrosooxan-4-yl) 4-[2-[4-(2-methylpropyl)phenyl]propanoyloxy]butanoate Chemical compound C1=CC(CC(C)C)=CC=C1C(C)C(=O)OCCCC(=O)OC1(N=O)CCOCC1 BWNIHXYJOYWRJE-UHFFFAOYSA-N 0.000 claims 1
- OSZNWMZVOCOYGQ-UHFFFAOYSA-N (4-nitrosooxan-4-yl) 4-acetyloxy-3-(acetyloxymethyl)but-2-enoate Chemical compound CC(=O)OCC(COC(C)=O)=CC(=O)OC1(N=O)CCOCC1 OSZNWMZVOCOYGQ-UHFFFAOYSA-N 0.000 claims 1
- TVBRWJUWDUMBRH-UHFFFAOYSA-N (4-nitrosooxan-4-yl) 4-acetyloxy-3-(acetyloxymethyl)butanoate Chemical compound CC(=O)OCC(COC(C)=O)CC(=O)OC1(N=O)CCOCC1 TVBRWJUWDUMBRH-UHFFFAOYSA-N 0.000 claims 1
- BWAOWCSBXMPCOM-UHFFFAOYSA-N (4-nitrosooxan-4-yl) 4-acetyloxybutanoate Chemical compound CC(=O)OCCCC(=O)OC1(N=O)CCOCC1 BWAOWCSBXMPCOM-UHFFFAOYSA-N 0.000 claims 1
- YZIIYDVNUPVASV-UHFFFAOYSA-N (4-nitrosooxan-4-yl) acetate Chemical compound CC(=O)OC1(N=O)CCOCC1 YZIIYDVNUPVASV-UHFFFAOYSA-N 0.000 claims 1
- YQOLEILXOBUDMU-KRWDZBQOSA-N (4R)-5-[(6-bromo-3-methyl-2-pyrrolidin-1-ylquinoline-4-carbonyl)amino]-4-(2-chlorophenyl)pentanoic acid Chemical compound CC1=C(C2=C(C=CC(=C2)Br)N=C1N3CCCC3)C(=O)NC[C@H](CCC(=O)O)C4=CC=CC=C4Cl YQOLEILXOBUDMU-KRWDZBQOSA-N 0.000 claims 1
- 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 claims 1
- QUZAOSQPCYKHBR-CCEZHUSRSA-N (E)-2,3,4,5,6-pentaacetyloxyhex-2-enoic acid Chemical compound CC(=O)OCC(OC(C)=O)C(OC(C)=O)C(\OC(C)=O)=C(/OC(C)=O)C(O)=O QUZAOSQPCYKHBR-CCEZHUSRSA-N 0.000 claims 1
- KQZLRWGGWXJPOS-NLFPWZOASA-N 1-[(1R)-1-(2,4-dichlorophenyl)ethyl]-6-[(4S,5R)-4-[(2S)-2-(hydroxymethyl)pyrrolidin-1-yl]-5-methylcyclohexen-1-yl]pyrazolo[3,4-b]pyrazine-3-carbonitrile Chemical compound ClC1=C(C=CC(=C1)Cl)[C@@H](C)N1N=C(C=2C1=NC(=CN=2)C1=CC[C@@H]([C@@H](C1)C)N1[C@@H](CCC1)CO)C#N KQZLRWGGWXJPOS-NLFPWZOASA-N 0.000 claims 1
- ONBQEOIKXPHGMB-VBSBHUPXSA-N 1-[2-[(2s,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxy-4,6-dihydroxyphenyl]-3-(4-hydroxyphenyl)propan-1-one Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1OC1=CC(O)=CC(O)=C1C(=O)CCC1=CC=C(O)C=C1 ONBQEOIKXPHGMB-VBSBHUPXSA-N 0.000 claims 1
- CEEJXUWTPWZLBL-AWEZNQCLSA-N 1-o-methyl 4-o-(4-nitrosooxan-4-yl) (2s)-2-(phenylmethoxycarbonylamino)butanedioate Chemical compound C([C@@H](C(=O)OC)NC(=O)OCC=1C=CC=CC=1)C(=O)OC1(N=O)CCOCC1 CEEJXUWTPWZLBL-AWEZNQCLSA-N 0.000 claims 1
- YRUQZISCBPYUHU-UHFFFAOYSA-N 1-o-methyl 4-o-(4-nitrosooxan-4-yl) butanedioate Chemical compound COC(=O)CCC(=O)OC1(N=O)CCOCC1 YRUQZISCBPYUHU-UHFFFAOYSA-N 0.000 claims 1
- RLRLANXNEZHCHO-LBPRGKRZSA-N 1-o-tert-butyl 4-o-(4-nitrosooxan-4-yl) (2s)-2-[(2-methylpropan-2-yl)oxycarbonylamino]butanedioate Chemical compound CC(C)(C)OC(=O)N[C@H](C(=O)OC(C)(C)C)CC(=O)OC1(N=O)CCOCC1 RLRLANXNEZHCHO-LBPRGKRZSA-N 0.000 claims 1
- KBVULDQKXUWUNV-UHFFFAOYSA-N 2,3,4,5,6-pentaacetyloxyhexanoic acid Chemical compound CC(=O)OCC(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(O)=O KBVULDQKXUWUNV-UHFFFAOYSA-N 0.000 claims 1
- FQMZXMVHHKXGTM-UHFFFAOYSA-N 2-(1-adamantyl)-n-[2-[2-(2-hydroxyethylamino)ethylamino]quinolin-5-yl]acetamide Chemical compound C1C(C2)CC(C3)CC2CC13CC(=O)NC1=CC=CC2=NC(NCCNCCO)=CC=C21 FQMZXMVHHKXGTM-UHFFFAOYSA-N 0.000 claims 1
- PYRKKGOKRMZEIT-UHFFFAOYSA-N 2-[6-(2-cyclopropylethoxy)-9-(2-hydroxy-2-methylpropyl)-1h-phenanthro[9,10-d]imidazol-2-yl]-5-fluorobenzene-1,3-dicarbonitrile Chemical compound C1=C2C3=CC(CC(C)(O)C)=CC=C3C=3NC(C=4C(=CC(F)=CC=4C#N)C#N)=NC=3C2=CC=C1OCCC1CC1 PYRKKGOKRMZEIT-UHFFFAOYSA-N 0.000 claims 1
- FMKGJQHNYMWDFJ-CVEARBPZSA-N 2-[[4-(2,2-difluoropropoxy)pyrimidin-5-yl]methylamino]-4-[[(1R,4S)-4-hydroxy-3,3-dimethylcyclohexyl]amino]pyrimidine-5-carbonitrile Chemical compound FC(COC1=NC=NC=C1CNC1=NC=C(C(=N1)N[C@H]1CC([C@H](CC1)O)(C)C)C#N)(C)F FMKGJQHNYMWDFJ-CVEARBPZSA-N 0.000 claims 1
- NPRYCHLHHVWLQZ-TURQNECASA-N 2-amino-9-[(2R,3S,4S,5R)-4-fluoro-3-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-7-prop-2-ynylpurin-8-one Chemical compound NC1=NC=C2N(C(N(C2=N1)[C@@H]1O[C@@H]([C@H]([C@H]1O)F)CO)=O)CC#C NPRYCHLHHVWLQZ-TURQNECASA-N 0.000 claims 1
- LFOIDLOIBZFWDO-UHFFFAOYSA-N 2-methoxy-6-[6-methoxy-4-[(3-phenylmethoxyphenyl)methoxy]-1-benzofuran-2-yl]imidazo[2,1-b][1,3,4]thiadiazole Chemical compound N1=C2SC(OC)=NN2C=C1C(OC1=CC(OC)=C2)=CC1=C2OCC(C=1)=CC=CC=1OCC1=CC=CC=C1 LFOIDLOIBZFWDO-UHFFFAOYSA-N 0.000 claims 1
- WYFCZWSWFGJODV-MIANJLSGSA-N 4-[[(1s)-2-[(e)-3-[3-chloro-2-fluoro-6-(tetrazol-1-yl)phenyl]prop-2-enoyl]-5-(4-methyl-2-oxopiperazin-1-yl)-3,4-dihydro-1h-isoquinoline-1-carbonyl]amino]benzoic acid Chemical compound O=C1CN(C)CCN1C1=CC=CC2=C1CCN(C(=O)\C=C\C=1C(=CC=C(Cl)C=1F)N1N=NN=C1)[C@@H]2C(=O)NC1=CC=C(C(O)=O)C=C1 WYFCZWSWFGJODV-MIANJLSGSA-N 0.000 claims 1
- KTRMRJFFPLUETK-UHFFFAOYSA-N 4-[methyl-[2-(4-nitrosooxan-4-yl)oxy-2-oxoethyl]amino]heptanedioic acid Chemical compound CN(CC(=O)OC1(CCOCC1)N=O)C(CCC(O)=O)CCC(O)=O KTRMRJFFPLUETK-UHFFFAOYSA-N 0.000 claims 1
- XFJBGINZIMNZBW-CRAIPNDOSA-N 5-chloro-2-[4-[(1r,2s)-2-[2-(5-methylsulfonylpyridin-2-yl)oxyethyl]cyclopropyl]piperidin-1-yl]pyrimidine Chemical compound N1=CC(S(=O)(=O)C)=CC=C1OCC[C@H]1[C@@H](C2CCN(CC2)C=2N=CC(Cl)=CN=2)C1 XFJBGINZIMNZBW-CRAIPNDOSA-N 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 125000006374 C2-C10 alkenyl group Chemical group 0.000 claims 1
- 125000005865 C2-C10alkynyl group Chemical group 0.000 claims 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims 1
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims 1
- 229940126657 Compound 17 Drugs 0.000 claims 1
- 229940126639 Compound 33 Drugs 0.000 claims 1
- OPFJDXRVMFKJJO-ZHHKINOHSA-N N-{[3-(2-benzamido-4-methyl-1,3-thiazol-5-yl)-pyrazol-5-yl]carbonyl}-G-dR-G-dD-dD-dD-NH2 Chemical compound S1C(C=2NN=C(C=2)C(=O)NCC(=O)N[C@H](CCCN=C(N)N)C(=O)NCC(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC(O)=O)C(N)=O)=C(C)N=C1NC(=O)C1=CC=CC=C1 OPFJDXRVMFKJJO-ZHHKINOHSA-N 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 1
- PNUZDKCDAWUEGK-CYZMBNFOSA-N Sitafloxacin Chemical compound C([C@H]1N)N(C=2C(=C3C(C(C(C(O)=O)=CN3[C@H]3[C@H](C3)F)=O)=CC=2F)Cl)CC11CC1 PNUZDKCDAWUEGK-CYZMBNFOSA-N 0.000 claims 1
- PSLUFJFHTBIXMW-WYEYVKMPSA-N [(3r,4ar,5s,6s,6as,10s,10ar,10bs)-3-ethenyl-10,10b-dihydroxy-3,4a,7,7,10a-pentamethyl-1-oxo-6-(2-pyridin-2-ylethylcarbamoyloxy)-5,6,6a,8,9,10-hexahydro-2h-benzo[f]chromen-5-yl] acetate Chemical compound O([C@@H]1[C@@H]([C@]2(O[C@](C)(CC(=O)[C@]2(O)[C@@]2(C)[C@@H](O)CCC(C)(C)[C@@H]21)C=C)C)OC(=O)C)C(=O)NCCC1=CC=CC=N1 PSLUFJFHTBIXMW-WYEYVKMPSA-N 0.000 claims 1
- HLZHVFIFZWDTLB-UHFFFAOYSA-N [2-(acetyloxymethyl)-4-(4-nitrosooxan-4-yl)oxy-4-oxobutyl] pyridine-3-carboxylate Chemical compound C1COCCC1(N=O)OC(=O)CC(COC(=O)C)COC(=O)C1=CC=CN=C1 HLZHVFIFZWDTLB-UHFFFAOYSA-N 0.000 claims 1
- XHWNYPUUHAOXQG-UHFFFAOYSA-N [2-[[2-(2-methoxyethoxy)acetyl]oxymethyl]-4-(4-nitrosooxan-4-yl)oxy-4-oxobutyl] pyridine-3-carboxylate Chemical compound C1COCCC1(N=O)OC(=O)CC(COC(=O)COCCOC)COC(=O)C1=CC=CN=C1 XHWNYPUUHAOXQG-UHFFFAOYSA-N 0.000 claims 1
- CUCWDEACWDLVNF-UHFFFAOYSA-N [4-(4-nitrosooxan-4-yl)oxy-4-oxo-2-(pyridine-3-carbonyloxymethyl)butyl] pyridine-3-carboxylate Chemical compound C=1C=CN=CC=1C(=O)OCC(COC(=O)C=1C=NC=CC=1)CC(=O)OC1(N=O)CCOCC1 CUCWDEACWDLVNF-UHFFFAOYSA-N 0.000 claims 1
- SMNRFWMNPDABKZ-WVALLCKVSA-N [[(2R,3S,4R,5S)-5-(2,6-dioxo-3H-pyridin-3-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl] [[[(2R,3S,4S,5R,6R)-4-fluoro-3,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-hydroxyphosphoryl]oxy-hydroxyphosphoryl] hydrogen phosphate Chemical compound OC[C@H]1O[C@H](OP(O)(=O)OP(O)(=O)OP(O)(=O)OP(O)(=O)OC[C@H]2O[C@H]([C@H](O)[C@@H]2O)C2C=CC(=O)NC2=O)[C@H](O)[C@@H](F)[C@@H]1O SMNRFWMNPDABKZ-WVALLCKVSA-N 0.000 claims 1
- XRWSZZJLZRKHHD-WVWIJVSJSA-N asunaprevir Chemical compound O=C([C@@H]1C[C@H](CN1C(=O)[C@@H](NC(=O)OC(C)(C)C)C(C)(C)C)OC1=NC=C(C2=CC=C(Cl)C=C21)OC)N[C@]1(C(=O)NS(=O)(=O)C2CC2)C[C@H]1C=C XRWSZZJLZRKHHD-WVWIJVSJSA-N 0.000 claims 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 claims 1
- KGNDCEVUMONOKF-UGPLYTSKSA-N benzyl n-[(2r)-1-[(2s,4r)-2-[[(2s)-6-amino-1-(1,3-benzoxazol-2-yl)-1,1-dihydroxyhexan-2-yl]carbamoyl]-4-[(4-methylphenyl)methoxy]pyrrolidin-1-yl]-1-oxo-4-phenylbutan-2-yl]carbamate Chemical compound C1=CC(C)=CC=C1CO[C@H]1CN(C(=O)[C@@H](CCC=2C=CC=CC=2)NC(=O)OCC=2C=CC=CC=2)[C@H](C(=O)N[C@@H](CCCCN)C(O)(O)C=2OC3=CC=CC=C3N=2)C1 KGNDCEVUMONOKF-UGPLYTSKSA-N 0.000 claims 1
- 229910052799 carbon Inorganic materials 0.000 claims 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims 1
- 125000004181 carboxyalkyl group Chemical group 0.000 claims 1
- 229940125758 compound 15 Drugs 0.000 claims 1
- 229940126142 compound 16 Drugs 0.000 claims 1
- 229940125782 compound 2 Drugs 0.000 claims 1
- 229940125810 compound 20 Drugs 0.000 claims 1
- 229940126086 compound 21 Drugs 0.000 claims 1
- 229940126208 compound 22 Drugs 0.000 claims 1
- 229940125833 compound 23 Drugs 0.000 claims 1
- 229940125961 compound 24 Drugs 0.000 claims 1
- 229940125877 compound 31 Drugs 0.000 claims 1
- 229940125878 compound 36 Drugs 0.000 claims 1
- 229940125807 compound 37 Drugs 0.000 claims 1
- 229940127573 compound 38 Drugs 0.000 claims 1
- 229940126540 compound 41 Drugs 0.000 claims 1
- 229940125936 compound 42 Drugs 0.000 claims 1
- 229940125844 compound 46 Drugs 0.000 claims 1
- 229940127113 compound 57 Drugs 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- JAXFJECJQZDFJS-XHEPKHHKSA-N gtpl8555 Chemical compound OC(=O)C[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@@H]1C(=O)N[C@H](B1O[C@@]2(C)[C@H]3C[C@H](C3(C)C)C[C@H]2O1)CCC1=CC=C(F)C=C1 JAXFJECJQZDFJS-XHEPKHHKSA-N 0.000 claims 1
- 150000002596 lactones Chemical group 0.000 claims 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- IOMMMLWIABWRKL-WUTDNEBXSA-N nazartinib Chemical compound C1N(C(=O)/C=C/CN(C)C)CCCC[C@H]1N1C2=C(Cl)C=CC=C2N=C1NC(=O)C1=CC=NC(C)=C1 IOMMMLWIABWRKL-WUTDNEBXSA-N 0.000 claims 1
- PIDFDZJZLOTZTM-KHVQSSSXSA-N ombitasvir Chemical compound COC(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@H]1C(=O)NC1=CC=C([C@H]2N([C@@H](CC2)C=2C=CC(NC(=O)[C@H]3N(CCC3)C(=O)[C@@H](NC(=O)OC)C(C)C)=CC=2)C=2C=CC(=CC=2)C(C)(C)C)C=C1 PIDFDZJZLOTZTM-KHVQSSSXSA-N 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
- 238000007911 parenteral administration Methods 0.000 claims 1
- 125000005415 substituted alkoxy group Chemical group 0.000 claims 1
- 238000006467 substitution reaction Methods 0.000 claims 1
- GBXQPDCOMJJCMJ-UHFFFAOYSA-M trimethyl-[6-(trimethylazaniumyl)hexyl]azanium;bromide Chemical compound [Br-].C[N+](C)(C)CCCCCC[N+](C)(C)C GBXQPDCOMJJCMJ-UHFFFAOYSA-M 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/56—Nitrogen atoms
- C07D211/58—Nitrogen atoms attached in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C207/00—Compounds containing nitroso groups bound to a carbon skeleton
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C207/00—Compounds containing nitroso groups bound to a carbon skeleton
- C07C207/04—Compounds containing nitroso groups bound to a carbon skeleton the carbon skeleton being further substituted by singly-bound oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C255/00—Carboxylic acid nitriles
- C07C255/01—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms
- C07C255/19—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms containing cyano groups and carboxyl groups, other than cyano groups, bound to the same saturated acyclic carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/40—Oxygen atoms
- C07D211/44—Oxygen atoms attached in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
- C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
- C07D309/08—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D309/10—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
- C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
- C07D309/08—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D309/14—Nitrogen atoms not forming part of a nitro radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
- C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
- C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D333/42—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms with nitro or nitroso radicals directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
- C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
- C07D407/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
- C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
- C07D451/04—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof with hetero atoms directly attached in position 3 of the 8-azabicyclo [3.2.1] octane or in position 7 of the 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring system
- C07D451/06—Oxygen atoms
- C07D451/10—Oxygen atoms acylated by aliphatic or araliphatic carboxylic acids, e.g. atropine, scopolamine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/06—Phosphorus compounds without P—C bonds
- C07F9/08—Esters of oxyacids of phosphorus
- C07F9/09—Esters of phosphoric acids
- C07F9/117—Esters of phosphoric acids with cycloaliphatic alcohols
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
- C07F9/576—Six-membered rings
- C07F9/58—Pyridine rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
- C07F9/576—Six-membered rings
- C07F9/59—Hydrogenated pyridine rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H13/00—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids
- C07H13/02—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids by carboxylic acids
- C07H13/04—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids by carboxylic acids having the esterifying carboxyl radicals attached to acyclic carbon atoms
- C07H13/06—Fatty acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
- C07C2601/14—The ring being saturated
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Pulmonology (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Hydrogenated Pyridines (AREA)
- Pyrane Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Saccharide Compounds (AREA)
- Heterocyclic Compounds Containing Sulfur Atoms (AREA)
Claims (16)
1. Spoj koji je nitrozo derivat formule VI ili njegova farmaceutski prihvatljiva sol:
[image]
gdje svaki R11a, R11b, R12a, R12b, R13a, R13b, R14a i R14b je H; i
gdje je D odabrano od
(i) grupe koja se sastoji od C1-C8alkil-C(O)-, perhaloalkil-C(O)-, C2-C10alkenil-C(O)-, C2-C10alkinil-C(O)-, C6-C14aril-C(O)-, heteroaril-C(O)- sa 5- ili 6-članim prstenom, heterociklil-C(O)- sa 5- ili 6-članim prstenom i -P(O)(OC1-C8alkil)2,
gdje svaki alkil, alkenil i alkinil je nesupstituiran ili supstituiran sa 1 do 5 supstituenata nezavisno odabranih od halo, nitro, cijano, okso, C6-C14aril, C1- C8alkoksi, C1-C8alkoksikarbonil, acil, aciloksi, acilamino, amino, hidroksil, karboksil, karboksil-C1-C8alkil, tiol, tio-C1-C8alkil, heterociklil sa 5- ili 6-članim prstenom, i -OS(O)2-C1-C8alkil, i
gdje svaki aril, heteroaril i heterociklil je nesupstituiran ili supstituiran sa 1 do 5 supstituenata nezavisno odabranih od halo, nitro, cijano, okso, C6-C14aril, C1-C8alkoksi, C1-C8alkil, acil, acilamino, amino, hidroksil, karboksil, karboksilC1-C8alkil, tiol, tioC1-C8alkil, heterociklil sa 5- ili 6-članim prstenom, i -OS(O)2-C1-C8alkil;
(ii) supstituiranog C1-C4alkil-C(O)- gdje je supstitucija jednog ili više supstituenata odabranih od aciloksi, CH3OCH2CH2OCH2C(O)O-, (acetil-OCH2)2CHN(acetil)-, (acetilOCH2)2CHN(Me)-, t-BuOC(O)NH-, PhCH2OC(O)NH- i C1-C8alkoksikarbonil; i
(iii) ostatka formule:
[image]
[image]
2. Spoj patentnog zahtjeva 1, gdje je D definirano kao u opciji (i).
3. Spoj patentnog zahtjeva 1 gdje je D struktura formule:
[image]
[image]
[image]
[image]
4. Spoj patentnog zahtjeva 1 gdje je spoj nitrozo derivat formule (VIa) ili njegova farmaceutski prihvatljiva sol:
[image]
gdje R3 je C1-C8alkil, perhaloC1-C8alkil, C2-C10alkenil, C2-C10alkinil, C6-C14aril, ili 5- ili 6-člana heteroarilna ili heterociklična grupa;
gdje svaki alkil, alkenil i alkinil je nesupstituiran ili supstituiran sa 1 do 5 supstituenata nezavisno odabranih od halo, nitro, cijano, okso, C6-C14aril, C1-C8alkoksi, C1-C8alkoksikarbonil, acil, aciloksi, acilamino, amino, hidroksil, karboksil, karboksil-C1-C8alkil, tiol, tio-C1-C8alkil, heterociklil sa 5- ili 6-članim prstenom, i -OS(O)2-C1-C8alkil, i
gdje svaki aril, heteroaril i heterociklil je nesupstituiran ili supstituiran sa 1 do 5 supstituenata nezavisno odabranih od halo, nitro, cijano, okso, C6-C14aril, C1- C8alkoksi, C1-C8alkil, acil, acilamino, amino, hidroksil, karboksil, karboksilC1-C8alkil, tiol, tioC1-C8alkil, heterociklil sa 5- ili 6-članim prstenom, i -OS(O)2-C1-C8alkil.
5. Spoj patentnog zahtjeva 4, gdje R3 je C1-C8 alkil supstituiran sa 1 do 5 supstituenata nezavisno odabranih od grupe koja se sastoji od hidroksil, alkoksi, aciloksi, acil, karboksil, karboksilalkil, alkoksikarbonil, i heterociklil.
6. Spoj patentnog zahtjeva 1 gdje spoj ima formulu (VIb):
[image]
gdje svaki R3a, R3b, R3c, R3d, R3e i R3f je nezavisno H, halo, hidroksil, alkoksi, supstituiran alkoksi, acil, aciloksi, nesupstituiran ili supstituiran alkil, perhaloalkil, nesupstituiran ili supstituiran alkenil, nesupstituiran ili supstituiran alkinil, nesupstituiran ili supstituiran aril, nesupstituiran ili supstituiran heteroaril, nesupstituiran ili supstituiran heterociklil, ili je uzet zajedno sa geminalnim R3a-f i ugljikom za koji su vezani da formiraju karbonil; i
R3g je H, nesupstituiran ili supstituiran alkil, perhaloalkil, nesupstituiran ili supstituiran alkenil, nesupstituiran ili supstituiran alkinil, nesupstituiran ili supstituiran aril, nesupstituiran ili supstituiran heteroaril, nesupstituiran ili supstituiran heterociklil, ili je uzet zajedno sa jednim od R3e i R3f da formira laktonski ostatak;
ili njegova farmaceutski prihvatljiva sol.
7. Spoj patentnog zahtjeva 1, gdje je spoj odabran od:
4-nitrozotetrahidro-2H-piran-4-il acetat (spoj 2);
4-nitrozotetrahidro-2H-piran-4-il 2,2,2-trifluoroacetat (spoj 15);
4-nitrozotetrahidro-2H-piran-4-il 3,3,3-trifluoropropanoat (spoj 16);
4-nitrozotetrahidro-2H-piran-4-il 4,4,4-trifluorobutanoat (spoj 17);
4-nitrozotetrahidro-2H-piran-4-il 2,2,2-trihloroacetat (spoj 20);
4-nitrozotetrahidro-2H-piran-4-il 2,2,3,3,3-pentafluoropropanoat (spoj 21);
4-nitrozotetrahidro-2H-piran-4-il 2-hloro-2,2-difluoroacetat (spoj 22);
(S)-4-nitrozotetrahidro-2H-piran-4-il 2-acetamido-3-fenilpropanoat (spoj 23);
4-nitrozotetrahidro-2H-piran-4-il pivalat (spoj 24);
4-nitrozotetrahidro-2H-piran-4-il 2-benzamidoacetat (spoj 31);
4-nitrozotetrahidro-2H-piran-4-il 2-acetamidopropanoat (spoj 32);
4-nitrozotetrahidro-2H-piran-4-il 3-(5-oksotetrahidrofuran-2-il)propanoat (spoj 33);
Metil 4-nitrozotetrahidro-2H-piran-4-il sukcinat (spoj 34);
2-metil-2-((4-nitrozotetrahidro-2H-piran-4-iloksi)karbonil)propan-1,3-diil diacetat (spoj 35);
4-nitrozotetrahidro-2H-piran-4-il 4-acetoksi-3-(acetoksimetil)butanoat (spoj 36);
1-metil 4-(4-nitrozotetrahidro-2H-piran-4-il) N-[(benziloksi)karbonil]aspartat (spoj 37);
1-terc-butil 4-(4-nitrozotetrahidro-2H-piran-4-il) N-(terc-butoksikarbonil)aspartat (spoj 38);
2-(metil(2-(4-nitrozotetrahidro-2H-piran-4-iloksi)-2-oksoetil)amino)propan-1,3-diildiacetat (spoj 40);
2-(N-(2-(4-nitrozotetrahidro-2H-piran-4-iloksi)-2-oksoetil)acetamido)propan-1,3-diil diacetat (spoj 41);
2-(acetoksimetil)-4-(4-nitrozotetrahidro-2H-piran-4-iloksi)-4-oksobutil nikotinat (spoj 42);
2-(2-(4-nitrozotetrahidro-2H-piran-4-iloksi)-2-oksoetil)propan-1,3-diil dinikotinat (spoj 43);
4-nitrozotetrahidro-2H-piran-4-il 4-acetoksibutanoat (spoj 44);
2-((2-(2-metoksietoksi)acetoksi)metil)-4-(4-nitrozotetrahidro-2H-piran-4-iloksi)-4-oksobutil nikotinat (spoj 45);
4-nitrozotetrahidro-2H-piran-4-il 4-({2-[4-(2-metilpropil)fenil]propanoil}-oksi)butanoat (spoj 46);
4-nitrozooksan-4-il (2R)-2-{[(terc-butoksi)karbonil]amino}propanoat (spoj 47);
4-nitrozotetrahidro-2H-piran-4-il 4-(acetiloksi)-3-[(acetiloksi)metil]but-2-enoat (spoj 48);
4-nitrozotetrahidro-2H-piran-4-il (2S,3S)-2,3,4-tris(acetiloksi)butanoat (spoj 50);
4-nitrozotetrahidro-2H-piran-4-il 2-acetiloksi)benzoat (spoj 51);
4-[(4-nitrozotetrahidro-2H-piran-4-il)oksi]-4-oksobutil 2-(acetiloksi)benzoat (spoj 52);
4-nitrozooksan-4-il 4-[(2-{1-metil-5-[(4-metilfenil)karbonil]-1H-pirol-2-il}acetil)oksi]butanoat (spoj 54);
4-nitrozooksan-4-il 2-[(2R,3S,4R,5S)-3,4,5,6-tetrakis(acetiloksi)oksan-2-il]acetat (spoj 55);
4-nitrozooksan-4-il 2-amino-3-hidroksipropanoat (spoj 56);
4-nitrozooksan-4-il (2E)-2,3,4,5,6-pentakis(acetiloksi)heks-2-enoat (spoj 57);
4-nitrozooksan-4-il 2,3,4,5,6-pentakis(acetiloksi)heksanoat (spoj 58);
i njegovih farmaceutski prihvatljivih soli.
8. Farmaceutska kompozicija koja sadrži (i) spoj prema bilo kojem od patentnih zahtjeva od 1-7 i (ii) farmaceutski prihvatljiv nosač.
9. Farmaceutska kompozicija prema patentnom zahtjevu 8 gdje je kompozicija pogodna za parenteralnu primjenu.
10. Spoj bilo kojeg od patentnih zahtjeva od 1 do 7 ili njegova farmaceutski prihvatljiva sol za primjenu u liječenju stanja odabranih od kardiovaskularne bolesti ili srčane insuficijencije, koronarnih opstrukcija, koronarne arterijske bolesti (CAD), angine, srčanog napada, infarkta miokarda, visokog krvnog pritiska, ishemijske kardiomiopatije i infarkta, dijastolne srčane insuficijencije, plućne kongestije, edema pluća, srčane fibroze, bolesti srčanog zalistka, perikardijalne bolesti, cirkulatornih kongestivnih stanja, perifernog edema, ascitesa, Chagasove bolesti, ventrikularne hipertrofije, bolesti srčanog zalistka, srčane insuficijencije, kongestivne srčane insuficijencije, akutne kongestivne srčane insuficijencije, akutne dekompenzovane srčane insuficijencije, plućne hipertenzije i srčane hipertrofije, ishemije/reperfuzione povrede, i kancerogenih bolesti.
11. Spoj patentnog zahtjeva 10 gdje je stanje kardiovaskularna bolest ili srčana insuficijencija.
12. Spoj patentnog zahtjeva 10 gdje je stanje odabrano iz grupe koju čine koronarne opstrukcije, koronarne arterijske bolesti (CAD), angina, srčani napad, infarkt miokarda, visoki krvni pritisak, ishemijska kardiomiopatija i infarkt, dijastolna srčana insuficijencija, plućna kongestija, edem pluća, srčana fibroza, bolest srčanog zalistka, perikardijalna bolest, cirkulatorna kongestivna stanja, periferni edem, ascites, Chagasova bolest, ventrikularna hipertrofija, bolest srčanog zalistka, srčana isuficijencija, kongestivna srčana insuficijencija, akutna kongestivna srčana insuficijencija, akutna dekompenzovana srčana insuficijencija, plućna hipertenzija i srčana hipertrofija.
13. Spoj patentnog zahtjeva 10 gdje je stanje ishemija/reperfuziona povreda.
14. Spoj patentnog zahtjeva 10 gdje je stanje kancerogena bolest.
15. Spoj patentnog zahtjeva 14 gdje je kancerogena bolest rak dojke, rak gušterače, rak prostate ili kolorektalni rak.
16. Upotreba spoja bilo kojeg patentnog zahtjeva od 1 do 7 ili njegove farmaceutski prihvatljive soli u proizvodnji lijeka za primjenu u liječenju stanja kao što je definirano u patentnim zahtevima 10-15.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US5128708P | 2008-05-07 | 2008-05-07 | |
PCT/US2009/043203 WO2009137717A1 (en) | 2008-05-07 | 2009-05-07 | Novel nitroso compounds as nitroxyl donors and methods of use thereof |
EP09743703.2A EP2278975B1 (en) | 2008-05-07 | 2009-05-07 | Novel nitroso compounds as nitroxyl donors and methods of use thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
HRP20161205T1 true HRP20161205T1 (hr) | 2016-11-18 |
Family
ID=41265021
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HRP20161205TT HRP20161205T1 (hr) | 2008-05-07 | 2016-09-21 | Novi nitrozo spojevi kao donori nitroksila i metode za njihovu upotrebu |
Country Status (16)
Country | Link |
---|---|
US (4) | US8318705B2 (hr) |
EP (2) | EP2278975B1 (hr) |
JP (2) | JP5654450B2 (hr) |
CN (2) | CN104945309B (hr) |
CA (1) | CA2723590C (hr) |
CY (1) | CY1118272T1 (hr) |
DK (1) | DK2278975T3 (hr) |
ES (1) | ES2601192T3 (hr) |
HR (1) | HRP20161205T1 (hr) |
HU (1) | HUE030372T2 (hr) |
LT (1) | LT2278975T (hr) |
MX (2) | MX344316B (hr) |
PL (1) | PL2278975T3 (hr) |
PT (1) | PT2278975T (hr) |
SI (1) | SI2278975T1 (hr) |
WO (1) | WO2009137717A1 (hr) |
Families Citing this family (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PL2278975T3 (pl) * | 2008-05-07 | 2017-02-28 | Cardioxyl Pharmaceuticals Inc. | Nowe związki nitrozowe jako donory nitroksylu i metody ich zastosowania |
WO2011063339A1 (en) | 2009-11-23 | 2011-05-26 | Cardioxyl Pharmaceuticals, Inc. | Nitroxyl donors for the treatment of pulmonary hypertension |
AU2010328230B2 (en) | 2009-12-07 | 2016-06-02 | Cardioxyl Pharmaceuticals, Inc. | Bis-acylated hydroxylamine derivatives |
MX2012006349A (es) * | 2009-12-07 | 2012-10-03 | Cardioxyl Pharmaceuticals Inc | Derivados de n-aciloxisulfonamida y n-hidroxi-n-acilsulfonamida. |
SG11201401587QA (en) | 2011-10-17 | 2014-07-30 | Univ Johns Hopkins | Meldrum 's acid, barbituric acid and pyrazolone derivatives substituted with hydroxylamine as hno donors |
EP3427728B1 (en) | 2013-01-18 | 2021-07-07 | Cardioxyl Pharmaceuticals, Inc. | Pharmaceutical compositions comprising nitroxyl donors |
EP3126329B1 (en) | 2014-01-17 | 2019-05-29 | Cardioxyl Pharmaceuticals Inc. | N-hydroxymethanesulfonamide nitroxyl donors |
US9464061B2 (en) | 2014-05-27 | 2016-10-11 | The Johns Hopkins University | N-hydroxylamino-barbituric acid derivatives |
WO2015183839A1 (en) | 2014-05-27 | 2015-12-03 | Cardioxyl Pharmaceuticals, Inc. | Pyrazolone derivatives as nitroxyl donors |
WO2015183838A1 (en) | 2014-05-27 | 2015-12-03 | The Johns Hopkins University | N-hydroxylamino-barbituric acid derivatives as nitroxyl donors |
ES2930848T3 (es) | 2015-09-23 | 2022-12-22 | Xwpharma Ltd | Profármacos de ácido gamma-hidroxibutírico, composiciones y usos de los mismos |
KR20180063326A (ko) | 2015-10-19 | 2018-06-11 | 카르디옥실 파마슈티칼스 인코포레이티드 | 니트록실 공여자로서의 피라졸론 유도체 |
WO2017070084A1 (en) | 2015-10-19 | 2017-04-27 | Cardioxyl Pharmaceuticals, Inc. | N-hydroxylsulfonamide derivatives as nitroxyl donors |
KR20190070912A (ko) | 2016-07-28 | 2019-06-21 | 더 존스 홉킨스 유니버시티 | O-치환된 히드록삼산 |
AU2017302660B2 (en) | 2016-07-29 | 2023-04-20 | Janssen Pharmaceutica Nv | Methods of treating prostate cancer |
WO2018128999A1 (en) | 2017-01-03 | 2018-07-12 | Cardioxyl Pharmaceuticals, Inc. | Method of administering nitroxyl donating compounds |
AU2017406159B2 (en) | 2017-03-30 | 2020-05-21 | XWPharma Ltd. | Bicyclic heteroaryl derivatives and preparation and uses thereof |
JP6996029B2 (ja) | 2018-09-30 | 2022-01-17 | エックスダブリューファルマ リミテッド | ニューロンヒスタミン受容体-3アンタゴニストとしての化合物およびその使用 |
CN115244028A (zh) | 2019-12-20 | 2022-10-25 | 凯瑞康宁生物工程有限公司 | 4-缬氨酰氧基丁酸的合成方法 |
EP4167966A1 (en) | 2020-06-18 | 2023-04-26 | XWPharma Ltd. | Pharmaceutical granulations of water-soluble active pharmaceutical ingredients |
JP2023537195A (ja) | 2020-06-18 | 2023-08-31 | エックスダブリューファーマ リミテッド | 水溶性医薬品有効成分の制御放出造粒物 |
WO2022020621A1 (en) | 2020-07-24 | 2022-01-27 | XWPharma Ltd. | Pharmaceutical compositions and pharmacokinetics of a gamma-hydroxybutyric acid derivative |
TW202228665A (zh) | 2020-10-05 | 2022-08-01 | 凱瑞康寧生技股份有限公司 | γ-羥基丁酸衍生物之修飾釋放組合物 |
EP4308086A1 (en) | 2021-03-19 | 2024-01-24 | XWPharma Ltd. | Pharmacokinetics of combined release formulations of a gamma-hydroxybutyric acid derivative |
CN114230495B (zh) * | 2021-11-24 | 2023-01-06 | 海南大学 | 一种氢化亚硝酰供体及其制备方法 |
Family Cites Families (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS567710A (en) | 1979-06-28 | 1981-01-27 | Sansho Seiyaku Kk | Whitening cosmetic |
EP0188040B1 (en) | 1985-01-11 | 1991-08-14 | Abbott Laboratories Limited | Slow release solid preparation |
US4663351A (en) | 1985-08-23 | 1987-05-05 | Berlex Laboratories, Inc. | Dobutamine tri-isobutyric acid ester and the use thereof as a cardiotonic agent |
US4798824A (en) | 1985-10-03 | 1989-01-17 | Wisconsin Alumni Research Foundation | Perfusate for the preservation of organs |
JP2773959B2 (ja) | 1990-07-10 | 1998-07-09 | 信越化学工業株式会社 | 大腸内放出性固形製剤 |
JPH07507200A (ja) * | 1991-09-20 | 1995-08-10 | ゼネカ リミテッド | ピラノン |
HU226559B1 (en) * | 1993-06-24 | 2009-03-30 | Amr Technology | Process for the production of piperidine derivatives |
US6596705B1 (en) * | 1998-02-09 | 2003-07-22 | The Regents Of The University Of California | Inhibition of L-selectin and P-selection mediated binding using heparin |
UA73092C2 (uk) | 1998-07-17 | 2005-06-15 | Брістол-Майерс Сквібб Компані | Таблетка з ентеросолюбільним покриттям і спосіб її приготування |
AU4800999A (en) | 1998-07-28 | 2000-02-21 | Tanabe Seiyaku Co., Ltd. | Preparation capable of releasing drug at target site in intestine |
US6355666B1 (en) * | 2000-06-23 | 2002-03-12 | Medinox, Inc. | Protected forms of pharmacologically active agents and uses therefor |
US20030068386A1 (en) | 2001-09-05 | 2003-04-10 | Stoyanovsky Detcho A. | Method of treating cancerous disease |
US20040038947A1 (en) | 2002-06-14 | 2004-02-26 | The Gov. Of The U.S. Of America As Represented By The Sec. Of The Dept. Of Health & Human Services | Method of treating ischemia/reperfusion injury with nitroxyl donors |
US6936639B2 (en) | 2002-08-21 | 2005-08-30 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Nitroxyl progenitors in the treatment of heart failure |
HUE030920T2 (en) | 2006-03-17 | 2017-06-28 | Univ Johns Hopkins | N-hydroxylsulfonamide derivatives as novel physiologically useful nitroxyl donors |
CA2648384A1 (en) | 2006-04-13 | 2007-10-25 | Wake Forest University Health Sciences | C-nitroso-derived nitroxyl donors |
DE102007062941B4 (de) * | 2007-12-21 | 2012-10-18 | Surface Technologies Gmbh & Co. Kg | Verfahren zur Herstellung eines Laminats |
PL2278975T3 (pl) * | 2008-05-07 | 2017-02-28 | Cardioxyl Pharmaceuticals Inc. | Nowe związki nitrozowe jako donory nitroksylu i metody ich zastosowania |
-
2009
- 2009-05-07 PL PL09743703T patent/PL2278975T3/pl unknown
- 2009-05-07 US US12/437,512 patent/US8318705B2/en active Active
- 2009-05-07 EP EP09743703.2A patent/EP2278975B1/en active Active
- 2009-05-07 PT PT97437032T patent/PT2278975T/pt unknown
- 2009-05-07 DK DK09743703.2T patent/DK2278975T3/en active
- 2009-05-07 CN CN201510245919.1A patent/CN104945309B/zh active Active
- 2009-05-07 LT LTEP09743703.2T patent/LT2278975T/lt unknown
- 2009-05-07 HU HUE09743703A patent/HUE030372T2/en unknown
- 2009-05-07 SI SI200931519A patent/SI2278975T1/sl unknown
- 2009-05-07 ES ES09743703.2T patent/ES2601192T3/es active Active
- 2009-05-07 MX MX2013013407A patent/MX344316B/es unknown
- 2009-05-07 CA CA2723590A patent/CA2723590C/en active Active
- 2009-05-07 CN CN200980124860.3A patent/CN102076342B/zh active Active
- 2009-05-07 WO PCT/US2009/043203 patent/WO2009137717A1/en active Application Filing
- 2009-05-07 JP JP2011508684A patent/JP5654450B2/ja active Active
- 2009-05-07 MX MX2010011924A patent/MX2010011924A/es active IP Right Grant
- 2009-05-07 EP EP16163363.1A patent/EP3067352A3/en not_active Withdrawn
-
2012
- 2012-10-18 US US13/654,937 patent/US8791134B2/en active Active
-
2014
- 2014-07-28 US US14/444,750 patent/US9732029B2/en active Active
- 2014-11-20 JP JP2014235732A patent/JP6192016B2/ja not_active Expired - Fee Related
-
2015
- 2015-10-30 US US14/927,994 patent/US9725402B2/en active Active
-
2016
- 2016-09-21 HR HRP20161205TT patent/HRP20161205T1/hr unknown
- 2016-12-01 CY CY20161101241T patent/CY1118272T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HRP20161205T1 (hr) | Novi nitrozo spojevi kao donori nitroksila i metode za njihovu upotrebu | |
Vatmurge et al. | Synthesis and antimicrobial activity of β-lactam–bile acid conjugates linked via triazole | |
ES2318527T3 (es) | Procedimiento de separacion de modafinilo. | |
AU2003211574A1 (en) | 8-azaprostaglandin derivative compounds and drugs containing the compounds as the active ingredient | |
JP2013533291A5 (hr) | ||
ES2861503T3 (es) | Agonistas de PPAR, compuestos, composiciones farmacéuticas y métodos de uso de los mismos | |
BR112015001608B1 (pt) | Métodos para purificação e síntese de um composto inibidor lfa-1, mistura reacional e composições compreendendo o dito composto e composto isolado inibidor lfa-1 | |
US20190077775A1 (en) | Process for the preparation of trisodium (4-{[1s,3r)-1-([1,1'-biphenyl]-4-ylmethyl)-4-ethoxy-3-methyl-4-oxobutyl]amino}-4-oxobutanoate)-(n-petanoyl-n-{[2'-(1h-tetrazol-1-1d-5-yl)[1,1'-biphenyl]-4-yl]methyl}- l-valinate) and its polymorphs thereof | |
CN105085322B (zh) | Ahu‑377中间体的制备方法及其中间体和中间体的制备方法 | |
BRPI0413848B1 (pt) | Composto, processo para preparar o composto, composição terapêutica para prevenir inflamação e apoptose, processo para preparar a composição terapêutica e uso de composto, ou de seu sal, ou de seu estereoisômero | |
JP2005504011A5 (hr) | ||
CA2648642A1 (en) | Niacin receptor agonists, compositions containing such compounds and methods of treatment | |
CN105085407A (zh) | 一种奥拉帕尼及其类似物的制备方法 | |
JP2005508380A5 (hr) | ||
KR101428111B1 (ko) | 시클로알칸카르복사미드 유도체 및 그의 제조 방법 | |
CN103958465B (zh) | 苯基衍生物 | |
US9376410B2 (en) | (2R)-2-deoxy-2,2-disubstituted-ribono-1,4-lactone and preparation method and use thereof | |
CN114031572A (zh) | 用于制备取代的环丝氨酸的方法 | |
Wang et al. | Stereoselective total synthesis of tubulysin V | |
CN105189454B (zh) | 苯基衍生物 | |
JP2020511450A5 (hr) | ||
CA3008698C (en) | Ginkgolide b derivative and preparation method and use thereof | |
CN112142746A (zh) | 苯二氮卓类化合物及其制备方法和在医药上的作用 | |
CN104341481A (zh) | 一种磺酰胺化合物的合成和应用 | |
CN104030998B (zh) | 4-多氟烷基-4,5-二取代异噁唑衍生物及其制备方法 |